Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating post-transplantation bendamustine and cyclophosphamide in refractory myeloid malignancies has completed.
-
CLINICAL_TRIALS research · 2024-09-27Clinical Trial Update: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy [NA]
Clinical trial evaluating how biological age and frailty influence management of chronic myeloid leukemia treated with targeted therapy; cur…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS [Phase 1]
Phase I study of CYC140, a PLK-1 inhibitor, in advanced leukemias and myelodysplastic syndromes has been terminated.
-
CLINICAL_TRIALS research · 2024-08-14Clinical Trial Update: CML Pediatric ITK Response According to Molecular Identification at Diagnosis
A pediatric chronic myeloid leukemia trial evaluating ITK response according to molecular identification at diagnosis is currently recruitin…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response [Phase 3]
Phase 3 clinical trial evaluating optimization of tyrosine kinase inhibitor therapy and quality of life in Philadelphia-positive chronic mye…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-08-07FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SCEMBLIX (asciminib) from Novartis, expanding its label for chronic myeloid leukemia in patients…
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia [Phase 2]
A Phase 2 clinical trial evaluating pegylated interferon alfa-2b in combination with nilotinib to augment complete molecular response in chr…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) [Phase 2]
Phase II study evaluating decitabine in chronic myeloid leukemia in blast phase patients refractory to imatinib; the trial status is complet…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias [Phase 1, Phase 2]
An early-phase study of escalating doses of AT9283 for various leukemias has been terminated.
-
CLINICAL_TRIALS research · 2024-08-01Clinical Trial Update: Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen [Phase 2]
Phase 2 clinical trial evaluating sorafenib as relapse prophylaxis after hematopoietic cell transplantation using the PTBCy regimen; the stu…
-
FDA approval · 2024-07-31FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories, resulting in an approved change to its labeling and/…
-
FDA approval · 2024-07-31FDA Approved: PHYRAGO — Supplemental Application (Cycle Pharmaceuticals Ltd)
The FDA approved a supplemental application for PHYRAGO (dasatinib) from Cycle Pharmaceuticals Ltd, indicating an update to the product's la…
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies [Phase 1, Phase 2]
Phase 1/Phase 2 trial update reporting safety and anti-leukemic activity of vodobatinib (K0706) in Ph+ chronic myeloid leukemia patients res…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Vitamin A and D Supplementation in Allogeneic HCT [Phase 2]
Phase 2 clinical trial in allogeneic hematopoietic cell transplantation is evaluating vitamin A and vitamin D supplementation, currently rec…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) [Phase 1]
A Phase 1 trial of HS-10382 in combination therapy for chronic myeloid leukemia is not yet recruiting.
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System [Phase 3]
Phase 3 study evaluating discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia and the impact on the immune system.
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression [Phase 3]
Phase 3 trial evaluating haploidentical allogeneic peripheral blood transplantation with analysis of checkpoint immune regulator expression;…
-
CLINICAL_TRIALS research · 2024-07-23Clinical Trial Update: Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib
Real-world evaluation of patient characteristics and treatment patterns in chronic myeloid leukemia in chronic phase patients treated with a…
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation [Phase 3]
Phase 3 trial results for asciminib as monotherapy in chronic myeloid leukemia in chronic phase, including patients with and without the T31…
-
FDA approval · 2024-06-18FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SCEMBLIX (asciminib) from Novartis Pharmaceuticals Corporation. The approval updates the drug's …
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant [Phase 1, Phase 2]
This clinical trial update examines using CD34+ malignant stem cell selection for patients receiving allogeneic stem cell transplants in Pha…
-
CLINICAL_TRIALS research · 2024-05-17Clinical Trial Update: Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission
A follow-up study is investigating treatment-free remission in patients with chronic myeloid leukemia; participant recruitment is ongoing.
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers [Phase 2]
A Phase 2 clinical trial update on haploidentical stem cell transplantation for multiple hematologic cancers, with the study status reported…
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Safety And Efficacy Of Bosutinib
This Clinical Trial Update reports on the safety and efficacy outcomes of bosutinib in patients with chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients [Phase 2]
A Phase 2 study evaluating azacitidine, venetoclax, and flumatinib in newly diagnosed Ph-positive acute leukemia and CML-AP/BP; the trial ha…